Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Invea Therapeutics Inc. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active prosecution involves 1 distinct examiner and 1 distinct art unit. The current state of the portfolio reflects a singular focus, as all pending regulatory interaction is confined to a single examiner and a single technical division.
The busiest examiner for this portfolio is SEITZ, ANTHONY JOSEPH, who is assigned 1 pending office action. Because the busiest examiner pending count is 1, the applicant is not currently dealing with multiple simultaneous actions from this examiner. This allows the practitioner to focus exclusively on the specific technical rejections or objections raised by this individual in the Biotechnology & Pharmaceuticals sector, as only 1 matter is assigned to this individual.
The presence of 1 pending office action indicates a very low volume of active disputes for the company at this time. Since there is only 1 distinct examiner and 1 distinct art unit involved, there is no risk of inconsistent prosecution across different applications. The strategy for this portfolio is currently defined by the resolution of this single pending matter within the Biotechnology & Pharmaceuticals sector. This focused approach ensures that all resources are directed toward the specific requirements of the current examination.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18208241 | SEVEN-MEMBERED RING COMPOUNDS AND METHOD OF USE THEREOF | SEITZ, ANTHONY JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18208241 | SEVEN-MEMBERED RING COMPOUNDS AND METHOD OF USE THEREOF | SEITZ, ANTHONY JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18208241 | SEVEN-MEMBERED RING COMPOUNDS AND METHOD OF USE THEREOF | SEITZ, ANTHONY JOSEPH | 1629 | §102§112 | Final Rejection | — | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInvea Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Anthony Joseph Seitz has the most, with 1 of Invea Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
